5-Amino-1MQ

Metabolic / Fat Loss Compound (NNMT Inhibitor)research

Also known as: 5-amino-1-methylquinolinium, NNMT inhibitor

A small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that promotes fat loss by increasing NAD+ levels and cellular energy metabolism, available as an oral compound.

Overview

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that plays a key role in cellular metabolism and energy expenditure. While technically not a peptide, it is commonly discussed alongside metabolic peptides due to its use in peptide-based fat loss protocols. NNMT is highly expressed in adipose tissue, and its overactivity is associated with obesity, metabolic syndrome, and reduced NAD+ availability. By inhibiting NNMT, 5-Amino-1MQ increases intracellular NAD+ levels, enhances cellular energy metabolism, and promotes the conversion of white adipose tissue toward a more metabolically active phenotype. Developed at the University of Texas Health Science Center, preclinical studies showed significant fat loss in diet-induced obese mice without changes in food intake, exercise, or lean mass. Its oral bioavailability makes it unique among fat-loss compounds in this space.

Mechanism of Action

5-Amino-1MQ acts through NNMT inhibition: (1) Blocks NNMT enzyme activity, preventing methylation and degradation of nicotinamide (NAM); (2) Increases intracellular NAD+ levels by preserving the NAM precursor pool; (3) Activates SIRT1 and other sirtuins through elevated NAD+, enhancing fat oxidation; (4) Promotes browning of white adipose tissue, increasing thermogenesis; (5) Reduces expression of lipogenic genes in adipocytes; (6) Enhances mitochondrial biogenesis and cellular energy expenditure; (7) Increases SAM (S-adenosylmethionine) availability, potentially affecting methylation reactions.

Molecular Formula

C10H13N2O

Molecular Weight

177.22 g/mol

Sequence

N/A โ€” small molecule, not a peptide

Dosage Protocols

Dose Range

50mg โ€“ 100mg

Frequency

Once daily

Route

oral

Cycle Length

8-12 weeks

Oral capsule form. Take in the morning with or without food. Some protocols use up to 150mg/day. Can be stacked with other fat-loss peptides (AOD 9604, HGH Fragment). No injection required.

Source: Clinic protocols and preclinical extrapolation

Side Effects

EffectSeverity
Mild GI discomfortmild
Headachemild
Insomniamild
Unknown long-term effectsunknown

Pros & Cons

โœ“

Oral bioavailability โ€” no injections required, making it highly convenient

โœ“

Promotes fat loss without affecting food intake, exercise requirements, or lean muscle mass

โœ“

Increases NAD+ levels, providing potential anti-aging and metabolic benefits beyond fat loss

โœ“

Novel mechanism distinct from stimulants, GLP-1 agonists, or thermogenics

โœ—

No human clinical trials โ€” all efficacy data from animal studies

โœ—

Not technically a peptide โ€” mechanism and long-term effects less familiar to the peptide community

โœ—

NNMT inhibition may have unintended consequences on methylation and other metabolic pathways

โœ—

Relatively expensive and available from limited sources

Research Studies

Legal Status

Not FDA-approved. Available as a research chemical. Increasingly offered by compounding pharmacies and peptide clinics. No specific scheduling or restrictions in most jurisdictions.

Related Peptides